For cancer patients with thromboembolism, the direct oral anticoagulant apixaban (Eliquis; Bristol-Myers Squibb) is noninferior to low-molecular-weight heparin (LMWH) for preventing recurrence of ...

The factor Xa inhibitor apixaban is noninferior to conventional therapy with enoxaparin and a vitamin K antagonist in patients with acute venous thromboembolism (VTE). The study, published online July ...

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...

Forbes contributors publish independent expert analyses and insights. I'm a medical journalist covering cardiology news. The AMPLIFY investigators randomized 5,395 patients with acute venous ...

Apixaban is also in Phase 3 trials studying the prevention of thrombotic events, such as stroke in patients with atrial fibrillation (AF). The AF program consists of: The ARISTOTLE trial, which is ...

If approved, healthcare professionals will be able to prescribe either Xarelto 10mg after patients have received at least 6 months of standard anticoagulation therapy Janssen has submitted a ...

The Appraisal Committee (section 7) considered evidence submitted by Bristol‑Myers Squibb and Pfizer, and a review of this submission by the Evidence Review Group (ERG; section 8). 3.1 The company ...